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In this study, we compared the entry processes of trans-complemented hepatitis C virus particles
(HCVtcp), cell culture-produced HCV (HCVcc) and HCV pseudoparticles (HCVpp). Anti-CD81 antibody
reduced the entry of HCVtcp and HCVcc to almost background levels, and that of HCVpp by
approximately 50%. Apolipoprotein E-dependent infection was observed with HCVtcp and HCVcc, but
not with HCVpp, suggesting that the HCVtcp system is more relevant as a model of HCV infection than
HCVpp. We improved the productivity of HCVtcp by introducing adapted mutations and by deleting
sequences not required for replication from the subgenomic replicon construct. Furthermore, blind
passage of the HCVtcp in packaging cells resulted in a novel mutation in the NS3 region, N1586D, which
contributed to assembly of infectious virus. These results demonstrate that our plasmid-based system
for efﬁcient production of HCVtcp is beneﬁcial for studying HCV life cycles, particularly in viral
assembly and infection.
& 2012 Elsevier Inc. All rights reserved.Introduction
Over 170 million people worldwide are chronically infected
with hepatitis C virus (HCV), and are at risk of developing chronic
liver diseases (Hoofnagle, 2002). HCV is an enveloped virus of the
family Flaviviridae, and its genome is a positive-strand RNA
consisting of the 50-untranslated region (UTR), an open reading
frame encoding viral proteins (core, E1, E2, p7, NS2, NS3, NS4A,
NS4B, NS5A, and NS5B) and the 30-UTR (Suzuki et al., 2007).
Host–virus interactions are required during the initial steps of viral
infection. It was previously reported that CD81 (Bartosch et al., 2003a,
b; McKeating et al., 2004; Pileri et al., 1998), scavenger receptor class
B type I (Bartosch et al., 2003a, b; Scarselli et al., 2002), claudin-1
(Evans et al., 2007; Liu et al., 2009) and occludin (Benedicto et al.,
2009; Evans et al., 2007; Liu et al., 2009; Ploss et al., 2009) are critical
molecules for HCV entry into cells. CD81 interacts with HCV E2 via a
second extracellular loop (Bartosch et al., 2003a, b; Hsu et al., 2003)
and its role in the internalization process was conﬁrmed (Cormier
et al., 2004; Flint et al., 2006). It has also been shown that infectiousll rights reserved.HCV particles produced in cell cultures (HCVcc) exist as apolipopro-
tein E (ApoE)-enriched lipoprotein particles (Chang et al., 2007) and
that ApoE is important for HCV infectivity (Owen et al., 2009).
Investigation of HCV had been hampered by difﬁculties in
amplifying the virus in vitro before development of robust cell culture
systems based on JFH-1 isolates (Lindenbach et al., 2005; Wakita
et al., 2005; Zhong et al., 2005). Retrovirus-based HCV pseudoparticles
(HCVpp), in which cell entry is dependent on HCV glycoproteins, have
been used to study virus entry (Bartosch et al., 2003a; Hsu et al.,
2003). Vesicular stomatitis virus (VSV)-based pseudotypic viruses
bearing HCV E1 and E2 and replication-competent recombinant VSV
encoding HCV envelopes have also been available as surrogate
models for studies of HCV infection (Mazumdar et al., 2011; Tani
et al., 2007).
It was recently shown that HCV subgenomic replicons can be
packaged when structural proteins are supplied in trans (Adair et al.,
2009; Ishii et al., 2008; Masaki et al., 2010; Steinmann et al., 2008).
These trans-complemented HCV particles (HCVtcp) are infectious,
but support only single-round infection and are unable to spread.
Establishment of ﬂexible systems to efﬁciently produce HCVtcp
should contribute to studying HCV assembly, in particular encapsi-
dation of the viral genome, and entry to cells with less stringent
biosafety and biosecurity measures. Although single-round infection
can be achieved by using the HCVcc system with receptor knock-out
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virus entry. We previously described plasmid-based production of
HCVcc and HCVtcp (Masaki et al., 2010). Here, we demonstrated
that HCVtcp production can be enhanced by introducing the
previously reported cell-culture adaptive mutations and by deleting
sequences not essential for replication in the subgenomic replicon
construct. By providing genotype 1b-derived core-to-p7 in addition
to intragenotypic viral proteins, chimeric HCVtcp were generated.
Furthermore, blind passage of HCVtcp in the packaging cells resulted
in the identiﬁcation of a novel cell culture-adaptive mutation in NS3
that enables us to establish the efﬁcient production of HCVtcp with
structural proteins from various strains. Taken together, our system
for producing single-cycle infectious HCV particles should be useful
in the study of entry and assembly steps of the HCV life cycles. This
technology may also have potential to be the basis for the safer
vaccine development.Fig. 1. HCVtcp production by two-plasmid transfection. (A) Schematic representation o
boxes. HCV UTRs are indicated by bold lines. The internal ribosomal entry site from enc
are indicated as asterisks. F Luc: ﬁreﬂy luciferase gene; CAG: CAG promoter; Pol I P: RN
deﬁcient GND mutation. (B) Luciferase activity in Huh7.5.1 cells inoculated with supern
Data are averages of triplicate values with error bars showing standard deviations. (C)Results
Enhancement of HCVtcp production by adaptive mutations in E2, p7
and NS2 and by deleting sequences not essential for replication from
replicon construct
In our HCVtcp system, the RNA polymerase I (Pol I)-driven
replicon plasmid, which carries a dicistronic subgenomic luciferase
reporter replicon of JFH-1 strain with a Pol I promoter and
terminator (pHH/SGR-Luc), as well as a plasmid containing core-
NS2 cDNA under the CAG promoter (pCAGC-NS2) were used
(Masaki et al., 2010). In an effort to improve the yield of HCVtcp
production, cell culture-adaptive mutations in E2 (N417S), p7
(N765D) and NS2 (Q1012R) which were previously selected from
serial passage of HCVcc (Russell et al., 2008) were introduced into
the core-NS2 expression plasmid (Fig. 1A) (residues are numberedf plasmids is shown. HCV polyproteins derived from JFH-1 are indicated by white
ephalomyocarditis virus (EMCV IRES) is denoted as gray lines. Adaptive mutations
A polymerase I promoter; Pol I T: RNA polymerase I terminator; GND: replication-
atant from cells transfected with indicated plasmids at the indicated time points.
Luciferase activity in cells inoculated with serially diluted HCVtcp.
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of cells transfected with plasmids (Fig. 1A) were collected and were
used to infect Huh7.5.1 cells, which were analyzed by luciferase
assay. Introduction of adaptive mutations (pCAGC-NS2/JFH1am)
resulted in more than 4-fold higher production of HCVtcp at 5 day
post-transfection, as compared to wild-type (WT) (pCAGC-NS2/
JFH1) (Fig. 1B), indicating that the adaptive mutations contribute
to enhancing HCVtcp production. To conﬁrm that luciferase activity
levels in HCVtcp-infected cells are correlated with the number of
infectious particles, Huh7.5.1 cells were inoculated with serial
dilutions of HCVtcp. Luciferase activity was well correlated with
viral load (Fig. 1C), indicating that luciferase assay in HCVtcp-
infected cells can be used to quantify HCV infection.
In order to further explore the efﬁcient production of HCVtcp,
we generated replicon constructs that lack the luciferase gene or
include the partial coding sequences for structural proteins
instead of reporter (Fig. 2A). Replication of each replicon in
plasmid-transfected cells was then assessed by Western blotting
(Fig. 2B). Among the constructs tested, NS5B levels were lowest in
cells expressing pHH/SGR-Luc. NS5B levels in cells replicating
other replicons appeared to be comparable. Cells were infected
with supernatants of cells transfected with each replicon plasmid,
along with pCAGC-NS2/JFH1am, followed by infectious unit assay
(Fig. 2C). The highest production of HCVtcp was obtained from
cells transfected with pHH/SGR, where the luciferase sequence
was deleted from pHH/SGR-Luc, thus suggesting that deletion of
the sequence not essential for RNA replication in the replicon may
contribute to enhancing HCVtcp production.Fig. 2. Production of HCVtcp with different replicon constructs. (A) Schematic represen
RNA from each construct is shown on the right. HCV polyproteins from JFH-1 strain are
denoted by gray bars. Adaptive mutations are indicated by asterisks. F Luc: ﬁreﬂy lu
(B) Detection of NS5B and actin in Huh7.5.1 cells transfected with indicated plasm
transfected with indicated replicon plasmids along with pCAGC-NS2/JFH1am at 4 dayProduction of chimeric HCVtcp by providing heterologous core-p7
In order to elucidate whether trans-encapsidation of JFH-1
replicon can be achieved by providing core-p7 from other HCV
strains, core-NS2 plasmids were constructed (Fig. 3A). In these
plasmids, core through the N-terminal 33 aa of NS2, which contains
transmembrane domain 1 of NS2, was derived from either H77c
(genotype 1a), THpa (genotype 1b), Con1 (genotype 1b) or J6
(genotype 2a) strain. Residual NS2 was derived from JFH-1, as
described previously (Pietschmann et al., 2006). HCVtcp was efﬁ-
ciently produced by core-p7 of J6 and THpa strains, but its produc-
tion was less efﬁcient in the case of Con1 strain. Trans-packaging
was not detectable when core-p7 of H77c strain was used (Fig. 3C).
Among HCV strains tested, difference in luciferase activity levels in
HCVtcp-infected cells (Fig. 3C) were in agreement with that in the
viral RNA levels in the culture supernatants of the transfected cells
(Fig. 3B). Although the efﬁcacy of trans-complementation was
variable among strains, chimeric HCVtcp can be generated by
providing genotype 1b-derived core-p7 in addition to intragenotypic
viral proteins, and was used in subsequent studies.
ApoE- and CD81-dependent infection by HCVtcp
There is accumulating evidence that apolipoproteins, particu-
larly ApoE, contribute to HCV production and infectivity (Chang
et al., 2007; Owen et al., 2009). To determine whether ApoE is
involved in infection of target cells by HCVtcp, we infected cells in
the presence of increasing concentrations of anti-ApoE antibody.tation of plasmids used for production of HCVtcp. Deduced length of transcribed
indicated by open boxes. HCV UTRs are indicated by bold lines. The EMCV IRES is
ciferase gene; P: RNA polymerase I promoter; T: RNA polymerase I terminator.
ids at 4 day post-transfection. (C) Infectivity of culture supernatants from cells
post-transfection.
Fig. 3. HCVtcp production with structural proteins from various strains. (A) Schematic representation of plasmids used. HCV polyproteins of JFH-1, J6, H77c, THpa and
Con1 strain are shown in the open box, bright gray box, box with diagonal lines, dark gray box and dotted box, respectively. (B) Relative levels of HCV RNA in the
supernatant from cells transfected with indicated plasmids along with pHH/SGR-Luc. (C) Luciferase activity in cells inoculated with supernatant from cells transfected with
indicated plasmids along with pHH/SGR-Luc at 4 day post-transfection.
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NS2 plasmids for HCVtcp production carrying core-p7 derived
from genotypes 1b and 2a (HCVtcp-1b and HCVtcp-2a, respec-
tively). HCVpp derived from JFH-1 and VSVpp were generated and
used for comparison. Infection with HCVtcp-1b or HCVtcp-2a was
blocked by anti-ApoE antibody in a dose-dependent manner. In
contrast, anti-ApoE antibody did not affect infection with HCVpp
and VSVpp (Fig. 4A).
The CD81 dependence of infection was also compared between
HCVtcp and HCVpp (Fig. 4B). Anti-CD81 antibody inhibited the
entry of HCVtcp-1b, HCVtcp-2a, and HCVpp in a dose-dependent
manner. The antibody had no effect on VSVpp infection. HCVtcp
infection appears to be more sensitive to anti-CD81 antibody
when compared with HCVpp infection; more than 60% inhibition
was observed at 0.08 mg/mL anti-CD81 antibody for HCVtcp-1b
and HCVtcp-2a, whereas approximately 50% inhibition was
observed for HCVpp at 2 mg/mL antibody. Neutralization of HCVcc
by anti-ApoE and anti-CD81 antibodies was also determined.
Antibodies blocked HCVcc infection (Fig. 4C and D), as observed
with HCVtcp. These results suggest that ApoE, as well as CD81,
play an important role in HCVtcp infection. Thus, HCVtcp may be
more useful for evaluating the HCV entry process than HCVpp.
Identiﬁcation of novel culture-adaptive mutation in NS3 by serial
passage of HCVtcp in packaging cells
The HCVtcp system was further applied to analyses of genetic
changes during serial passages in target cells. As an initial attempt,
supernatants of cells co-transfected with pCAGC-NS2/JFH1am and
pHH/SGR were inoculated into Huh7.5.1 cells transiently trans-
fected with pCAGC-NS2/JFH1am. However, infectious titer was
lost after repeated inoculation, likely due to low HCVtcp titers andlow efﬁciency of plasmid transduction (data not shown). To
overcome this, we utilized recombinant adenovirus vectors
(rAdVs) to provide core-NS2. As we were not able to obtain rAdV
directly expressing core-NS2, conditional transgene expression
based on a Cre-loxP strategy was employed (Kanegae et al.,
1995). We constructed an rAdV containing core-NS2 gene down-
stream of a stuffer DNA ﬂanked by a pair of loxP sites (AxCALNLH-
CNS2). When cells were doubly infected with AxCALNLH-CNS2
and the Cre-expressing rAdV, AxCANCre (Kanegae et al., 1995), the
Cre-mediated excisional deletion removed the stuffer DNA, result-
ing in core-NS2 expression under control of the CAG promoter
(Fig. 5A). As expected, tightly regulated production of HCVtcp was
observed. The cells infected with AxCANCre and AxCALNLH-CNS2
along with transduction of pHH/SGR-Luc produced HCVtcp at high
levels. Production of HCVtcp was undetectable when either
AxCANCre or AxCALNLH-CNS2 was not infected (Fig. 5B). The
Cre-mediated rAdV expression system appears to have yielded
considerably higher production of HCVtcp when compared with
the settings for plasmid co-transfection.
Supernatants from cells in which core-NS2 was expressed
using rAdVs and the subgenomic RNA derived from pHH/SGR
replicated were inoculated into cells infected with AxCALNLH-
CNS2 and AxCANCre (Fig. 6A). Blind passage was performed by
sequentially transferring culture supernatants to cells infected
with the above rAdVs. The two independent 10 blind passages
(p10) showed virus titers of 41106 IU/mL, which were mark-
edly higher than those of the passage 0 (p0) stock cultures
(4104 IU/mL). Side-by-side infection analysis revealed that the
HCVtcp p10 #1 achieved a virus titer approximately 36 times
higher than that of HCVtcp p0 on the packaging cells at 6 day
post-infection (Fig. 6B). Sequencing of the entire replicon in the
supernatants at p10 in two independent experiments revealed
Fig. 4. Effects of anti-ApoE and anti-CD81 antibodies on HCV entry. (A) Aliquots of virus sample were incubated with increasing concentrations of anti-ApoE antibodies for
1 h and were then added to Huh7.5.1 cells. Luciferase activity was determined at 72 h post-infection and is expressed relative to activity without antibodies (white bar).
(B) Huh7.5.1 cells were preincubated for 1 h with increasing concentrations of anti-CD81 antibodies, followed by inoculating virus samples. Luciferase activity was
determined and expressed as shown in (A). (C) Aliquots of HCVcc were incubated with anti-ApoE antibodies for 1 h and were then added to Huh7.5.1 cells at an MOI of
0.05. Intracellular core levels were quantitated at 24 h post-infection and are expressed relative to levels without antibodies (white bar). (D) Huh7.5.1 cells were
preincubated for 1 h with anti-CD81 antibodies. HCVcc infection and measurement of core proteins were performed as indicated in (C).
Fig. 5. Transgene activation mediated by rAdVs expressing Cre recombinase under control of CAG promoter. (A) Cre recobminase expressed by AxCANCre recognizes a pair
of its target sequences loxP in AxCALNLH-CNS2, and removes the stuffer region resulting in expression of HCV core-NS2 polyprotein by CAG promoter. CAG: CAG promoter;
SpA: SV40 early polyA signal; GpA: rabbit b-globin poly(A) signal. (B) Luciferase activity in Huh7.5.1 cells inoculated with 4-day post-transfection culture supernatant from
cells transfected with pHH/SGR-Luc, and then infected with indicated rAdVs.
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mutation in the NS3 region (N1586D) (Fig. 6C).
In order to examine the role of NS3 mutation identiﬁed on HCV
RNA replication and on HCVtcp production, the N1586D mutation
was introduced into pHH/SGR-Luc. Luciferase activities of the
N1586D-mutated replicon were apparently lower than those of
the WT-replicon, thus suggesting that the NS3 mutation reduced
viral RNA replication (Fig. 7A). HCV RNA levels in the supernatants
of cells transfected with WT- or mutant replicon plasmid along with
pCAGC-NS2/JFH1am and luciferase activity in cells inoculated with
supernatants from the transfected cells were then determined
(Fig. 7B). The viral RNA level secreted from cells replicating the
N1586D-mutated replicon was lower than that from cells replicating
WT replicon (Fig. 7B, left). By contrast, a signiﬁcantly higher
infectivity of HCVtcp produced from the mutant replicon-cells was
observed, as compared to WT replicon-cells (Fig. 7B, right),suggesting that the adaptive mutation increased the speciﬁc infec-
tivity (almost 9-fold) of the virus particles. To further determine
whether the N1586Dmutation affects infectious viral assembly and/
or virus release, we used the CD81-negative Huh-7 subclone, Huh7-
25 (Akazawa et al., 2007), which may produce infectious particles,
but is not susceptible to HCV entry due to a lack of CD81 expression,
therefore allowing us to examine viral assembly and release without
the inﬂuence of reinfection by produced HCVtcp. Measurement of
intracellular and extracellular HCVtcp indicated that Huh7-25 cells
replicating the N1586D-mutated replicon produced more infectious
virus thanWT in both supernatants and cell lysates (Fig. 7C). Thus, it
can be concluded that the N1586D mutation contributes to
enhanced infectious viral assembly, not RNA replication. We could
not exclude the possibility that N1586D mutation affects virus
release, since the mutation enhanced extracellular virus titers more
than did the intracellular titer.
Fig. 6. Genotypic changes in HCVtcp following blind passage. (A) Experimental procedure for blind passage of HCVtcp. Huh7.5.1 cells were transfected with pHH/SGR and
were doubly infected with AxCANCre and AxCALNLH-CNS2. Culture ﬂuids were collected and were inoculated into cells infected with AxCANCre and AxCALNLH-CNS2.
These procedures were repeated 10 times with two independent samples (#1 and #2). (B) Growth curves of HCVtcp p0 and p10 on Huh7.5.1 cells expressing core-NS2.
Cells were infected with HCVtcp at an MOI of 0.05, and medium was collected at the indicated time points and subjected to titration. (C) Nucleotide sequences of original
and blind-passaged replicons from HCVtcp. Nucleotides of mutated position are shown in red and bold.
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and intergenotypic HCVtcp chimeras was also investigated. The
N1586D mutation in the replicon enhanced the production of
chimeric HCVtcp by providing core-p7 from all strains examined,
although not statistically signiﬁcant in THpa, and Con1 strains
(Fig. 7D). Finally, to determine whether the N1586D mutation
was responsible for enhancing HCVcc production, this mutation
was introduced into pHHJFH1, which carries the full-length wild-
type JFH-1 cDNA (Masaki et al., 2010), yielding pHHJFH1N1586D.
The virus titer obtained from cells transfected with the
pHHJFH1N1586D was signiﬁcantly higher than that of WT
(Fig. 7E), thus demonstrating that the N1586D mutation enhances
yields of HCVcc, in addition to HCVtcp.Discussion
Single-round infectious viral particles generated by trans-
packaging systems are considered to be valuable tools for study-
ing virus life cycles, particularly the steps related to entry into
target cells, assembly and release of infectious particles. However,
limited HCV strains have been applied for the efﬁcient production
of HCVtcp to date. In this study, we improved the HCVtcp system
in order to enhance the productivity of infectious particles.
Production of chimeric HCVtcp by providing genotype 1b-derived
core-p7, in addition to intragenotypic viral proteins, was also
conﬁrmed. Furthermore, we exploited the system to investigate
genetic changes during serial passage of target cells and identiﬁed
a novel cell culture-adaptive mutation in NS3, which also con-
tributes to enhance the productivity of HCVtcp.
HCVpp (Bartosch et al., 2003a; Hsu et al., 2003) has proven to
be a valuable surrogate system by which the study of viral and
cellular determinants of the viral entry pathway is possible. Early
steps of HCV infection, including the role of HCV glycoprotein
heterodimers, receptor binding, internalization and pH-depen-
dent endosomal fusion, have been at least in part mimicked by
HCVpp (Lavie et al., 2007). However, as HCVpp is generated in
non-hepatic cells such as the human embryo kidney cells 293T, itis likely that the cell-derived component(s) of HCVpp differ from
those of HCVcc. Hepatocytes play a role in maintaining lipid
homeostasis in the body by assembling and secreting lipopro-
teins, including VLDL. It is highly likely that HCV exploits lipid
synthesis pathways, as there is a tight link between virion
formation and VLDL synthesis. Down-regulation of ApoE consid-
erably reduces HCV production (Benga et al., 2010; Chang et al.,
2007; Hishiki et al., 2010; Jiang and Luo, 2009; Owen et al., 2009).
Infectivity of HCVcc is also neutralized by anti-ApoE antibodies
(Chang et al., 2007). These data suggest that ApoE is important for
HCV infectivity. Furthermore, Niemann-Pick C1-like 1 (NPC1L1),
involving cholesterol uptake receptor, was recently identiﬁed as a
host factor for HCV entry (Sainz et al., 2012). Knockdown of
NPC1L1 had no effect on the entry of HCVpp whereas HCVcc entry
was impaired, possibly due to different cholesterol content of
these particles. Here, we found that the anti-ApoE antibody
neutralized infection by HCVtcp and HCVcc, but not by HCVpp
(Fig. 4A and C), thus suggesting that biogenesis and/or secretion
pathways of VLDL are involved in HCVtcp similarly to HCVcc, but
not in HCVpp.
We also observed that infectivity of HCVtcp and HCVcc is more
efﬁciently neutralized by the anti-CD81 antibody, as compared to
that of HCVpp (Fig. 4B and D). It has recently been reported that
E2 of HCVcc contained both high-mannose-type and complex-
type glycans, whereas most of the glycans on HCVpp-associated
E2 were complex-type, which is matured by Golgi enzymes
(Vieyres et al., 2010). Mutational analysis of the N-linked glyco-
sylation sites in E1/E2 demonstrated that several glycans on E2
may affect the sensitivity of HCVpp against antibody neutraliza-
tion, as well as access of CD81 to its binding site on E2 (Helle
et al., 2010). The differences in sensitivity between HCVtcp and
HCVpp to neutralization by anti-CD81 antibody observed here
may be due to differences in carbohydrate composition of HCV
glycoproteins during expression and processing of E1/E2 in cells
and morphogenesis of HCVtcp and HCVpp.
By analyzing the various replicons for trans-packaging, we
observed the highest production of HCVtcp with replicons
from pHH/SGR, which lacked sequences not essential for RNA
Fig. 7. Effects of N1586D mutation on RNA replication and production of HCVtcp or HCVcc. (A) RNA replication of replicons in cells transfected with pHH/SGR-Luc (WT) or N1586D
mutant. Luciferase activities at 1 to 4 day post-transfection were determined. (B) Relative levels of HCV RNA in the supernatants from cells transfected with pHH/SGR-Luc (WT) or
N1586D mutant plasmid along with pCAGC-NS2/JFH1am were shown in the left panel. Luciferase activities in cells inoculated with supernatants from cells transfected with
indicated plasmids at 4 day post-transfection were shown in the right panel. (C) Luciferase activity in cells inoculated with supernatant and cell lysates from Huh7-25 cells
transfected with pHH/SGR-Luc (WT) or N1586D mutant plasmid along with pCAGC-NS2/JFH1am at 5 day post-transfection. (D) Luciferase activity in cells inoculated with culture
supernatant from cells transfected with pHH/SGR-Luc (WT) or N1586D mutant plasmid along with indicated core-NS2 plasmids at 4 day post-transfection. (E) Infectivity of
supernatant from cells transfected with pHH/JFH1 (WT) or its derivative plasmid containing N1586D mutation at 6 day post-transfection. Statistical differences between WT and
N1586D were evaluated using Student’s t-test. npo0.05, nnpo0.005 vs. WT.
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pHH/SGR-Luc, pHH/SGR-C177, pHH/SGR-C191 and pHH/SGR-C-
p7/am (Fig. 2C). Differences in the replication efﬁciency of the
replicon do not appear to be a major determinant for HCVtcp
productivity, at least in the present settings, as all replicon
constructs except pHH/SGR-Luc replicated at similar levels, as
conﬁrmed by Western blotting (Fig. 2B). Although the shorter
viral genome sequence may offer advantages over the longer
sequence, further investigation is required in order to understand
the molecular mechanisms underlying viral genome packaging.
By comparing pHH/SGR vs. pHH/SGR-C177, pHH/SGR-C191 and
pHH/SGR-C-p7/am, it is likely that the expression of the structural
protein in cis does not increase HCVtcp production when sufﬁ-
cient amounts of structural proteins are supplied in trans.
Blind passage of HCVtcp in packaging cells infected with rAdVs
providing core-NS2 enabled us to identify a novel culture-adaptive
mutation in NS3. The N-terminal third of NS3 forms a serine
protease, together with NS4A, and its C-terminal two-thirds exhibits
RNA helicase and RNA-stimulated NTPase activities. In addition,
similarly to ﬂaviviruses (Kummerer and Rice, 2002; Liu et al., 2002),
it is now apparent that HCV NS3 is also involved in viralmorphogenesis (Han et al., 2009; Ma et al., 2008), although its
precise role and underlying molecular mechanism(s) have not fully
been elucidated. Two cell-culture adaptive NS3 mutations which are
involved in HCV assembly have been identiﬁed. The Q1251L muta-
tion in helicase subdomain 1 resulted in approximately 30-fold
higher production of HCV without affecting NS3 enzymatic activities
(Ma et al., 2008). The M1290K adaptive mutation was also located in
subdomain 1 of the NS3 helicase (Han et al., 2009). The N1586D
mutation identiﬁed here was located in subdomain 3 of helicase.
Analogous to Q1251L and M1290K, the N1586D mutation enhanced
the infectious viral assembly by increasing speciﬁc infectivity with-
out affecting the efﬁciency of viral RNA replication. Considering the
possibility that NS3 plays a role in linking between the viral
replicase and assembly sites (Jones et al., 2011), it is likely that
NS3 helicase is one of the determinants for interaction with the
structural proteins. Our results, together with earlier studies, suggest
that chimeric and defective mutations as well as supplying the viral
components in trans, function as selective pressures in virion
assembly.
In summary, we have established a plasmid-based reverse
genetics for efﬁcient production of HCVtcp with structural
R. Suzuki et al. / Virology 432 (2012) 29–3836proteins from various strains. Single-round infectious HCVtcp can
complement the HCVcc and HCVpp systems as a valuable tool for
the study of HCV life cycles.Materials and methods
Cells
Huh7 derivative cell line Huh7.5.1 and Huh7-25 were main-
tained in Dulbecco modiﬁed Eagle medium (DMEM) supplemen-
ted with nonessential amino acids, 100 U of penicillin/mL, 100 mg
of streptomycin/mL, and 10% fetal bovine serum at 37 1C in a 5%
CO2 incubator.Plasmids
Plasmids pHHJFH1, pHH/SGR-Luc, pHH/SGR-Luc/GND and
pCAG/C-NS2 were as described previously (Masaki et al., 2010).
In this study, plasmid pCAG/C-NS2 was designated as pCAGC-
NS2/JFH. The plasmid pCAGC-NS2/JFHam having adaptive muta-
tions in E2 (N417S), p7 (N765D), and NS2 (Q1012R) in pCAGC-
NS2/JFH was constructed by oligonucleotide-directed mutagen-
esis. These mutations were also introduced in pHHJFH1, resulting
in pHHJFH1am. To generate core-NS2 expression plasmids with
different strains of HCV, the cDNA coding core to the ﬁrst
transmembrane region of NS2 (33 amino acids) in pCAGC-NS2/
JFH was replaced with the corresponding sequence of the J6
(Lindenbach et al., 2005), H77c (Yanagi et al., 1997), THpa
(Shirakura et al., personal communication) and Con1 (Koch and
Bartenschlager, 1999) strains. The THpa sequence contained the P
to A mutation at 328 aa at E1 in the original TH strain. To generate
pHH/SGR, pHH/SGR-Luc was digested with MluI and PmeI, fol-
lowed by Klenow enzyme treatment and self-ligation to delete
the luciferase coding sequence. To generate pHH/SGR-C177, pHH/
SGR-C191 and pHH/SGR-C-p7/am, cDNA coding the partial core
and luciferase in pHH/SGR-Luc were replaced with coding
sequences for mature core (177aa), full-length core (191aa) or
core-p7 polyprotein containing adaptive mutations in E2 and p7,
respectively. The selected NS3 mutation (N1586D) was intro-
duced into pHH/SGR-Luc and pHHJFH1 by oligonucleotide-direc-
ted mutagenesis.Generation of viruses
HCVcc and HCVtcp were generated as described previously
(Masaki et al., 2010). For the production of HCVpp-2a, plasmid
pcDNAdeltaC-E1-E2(JFH1)am having adaptive mutations in E2
(N417S) in pcDNAdeltaC-E1-E2(JFH1) (Akazawa et al., 2007) was
constructed by oligonucleotide-directed mutagenesis. Murine
leukemia virus pseudotypes with VSV G glycoprotein expressing
luciferase reporter (VSVpp) were generated in accordance with
previously described methods (Akazawa et al., 2007; Bartosch
et al., 2003a).Luciferase assay
Huh7.5.1 cells were seeded onto a 24-well plate at a density of
3104 cells/well 24 h prior to inoculation with reporter viruses.
Cells were incubated for 72 h, followed by lysis with 100 mL of
lysis buffer. Luciferase activity of the cells was determined using a
luciferase assay system (Promega, Madison, WI). All luciferase
assays were performed in triplicate.Quantiﬁcation of HCV infectivity and HCV RNA
To determine the titers of HCVtcp and HCVcc, Huh7.5.1 cell
monolayers prepared in multi-well plates were incubated with
dilutions of samples and then replaced with media containing
10% FBS and 0.8% carboxymethyl cellulose. Following incubation
for 72 h, monolayers were ﬁxed and immunostained with rabbit
polyclonal anti-NS5A antibody, followed by Alexa Fluor 488-
conjugated anti-rabbit secondary antibody (Invitrogen), and
stained foci or individual cells were counted and used to calculate
a titer of focus-forming units (FFU)/mL for spreading infections or
infectious units (IU)/mL for non-spreading infections. For intra-
cellular infectivity, the cell pellet was resuspended in culture
media, and cells were lysed by four freeze–thaw cycles. Cell
debris was pelleted by centrifugation for 5 min at 4000 rpm.
Supernatant was collected and used for titration. To determine
the amount of HCV RNA in culture supernatants, RNA was
extracted from 140 mL of culture medium by QIAamp Viral RNA
Mini Kit (QIAGEN, Valencia, CA) and treated with DNase (TURBO
DNase; Ambion, Austin, TX) at 37 1C for 1 h. Extracted RNA was
further puriﬁed by using an RNeasy Mini Kit, which includes
RNase-free DNase digestion (QIAGEN). Copy numbers of HCV RNA
were determined by real-time quantitative reverse transcription-
PCR as described previously (Wakita et al., 2005).
Antibodies
Mouse monoclonal antibodies against actin (AC-15) and CD81
(JS-81) were obtained from Sigma (St. Louis, MO) and BD
Biosciences (Franklin Lakes, NJ), respectively. Goat polyclonal
antibody to ApoE (LV1479433) was obtained from Millipore
(Tokyo, Japan). Anti-NS5A and anti-NS5B antibodies were rabbit
polyclonal antibody against synthetic peptides.
Neutralization assay
For neutralization experiments with anti-CD81 antibody,
Huh7.5.1 cells were incubated with dilutions of anti-CD81 anti-
body for 1 h at 37 1C. Cells were then infected with viruses for 5 h
at 37 1C. For neutralization experiments with anti-ApoE antibody,
viruses were incubated with various concentrations of anti-ApoE
antibody at room temperature for 1 h and cells were infected with
viruses for 5 h at 37 1C. Following infection, supernatant was
removed and cells were incubated with culture medium, and
luciferase activity was determined at 3 day post-infection for
HCVtcp and pseudotyped viruses. For neutralization experiments
with HCVcc generated with pHHJFH1am, a multiplicity of infec-
tion (MOI) of 0.05 was used for inoculation, and intracellular core
protein levels were monitored by ELISA (Ortho Clinical Diagnos-
tics) at 24 h post-infection.
Immunoblotting
Transfected cells were washed with PBS and incubated with
lysis buffer (50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 1% triton
X-100). Lysates were then sonicated for 5 min and were added to
the same volume of SDS sample buffer. Protein samples were
boiled for 10 min, separated by SDS-PAGE, and transferred to
PVDF membrane. After blocking, membranes were probed with
ﬁrst antibodies, followed by incubation with peroxidase-conju-
gated secondary antibody. Antigen–antibody complexes were
visualized using an enhanced chemiluminescence detection sys-
tem (Super Signal West Pico Chemiluminescent Substrate;
PIERCE, Rockford, IL), in accordance with the manufacturer’s
protocols.
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rAdV, AxCANCre, expressing Cre recombinase tagged with
nuclear localization signal under CAG promoter was prepared as
described previously (Baba et al., 2005). The target rAdV
AxCALNLH-CNS2 expressing HCV core-NS2 polyprotein with
adaptive mutations in E2, p7 and NS2 was generated as follows.
Cosmid pAxCALNLwit2 is identical to pAxCALNLw (Sato et al.,
1998), except that both the terminal sequences of the rAdV
genome are derived from pAxCAwit2 (Fukuda et al., 2006). The
core-NS2 fragment obtained from pCAGC-NS2/JFH1am by StuI-
EcoRI digestion and subsequent Klenow treatment was inserted
into the SwaI site of pAxCALNLwit2. The resultant cosmid pAx-
CALNLH-CN2it2 was digested with PacI and transfected into 293
cells to generate rAdV AxCALNLH-CNS2.
Preparation of packaging cells for HCVtcp
Huh7.5.1 cells were coinfected with AxCANCre at an MOI of
1 and AxCALNLH-CNS2 at an MOI of 3 for expression of JFH-1
core-NS2 polyprotein containing the adaptive mutations in E2, p7
and NS2.
RNA preparation, RT-PCR and sequencing
Total cellular RNA was extracted with TRIzol reagent (Invitro-
gen, Carlsbad, CA), and subjected to reverse transcription with
random hexamer and Superscript III reverse transcriptase (Invi-
trogen). Three fragments of HCV cDNAs that cover the entire HCV
subgenomic replicon genome, were ampliﬁed by nested PCR with
TaKaRa Ex Taq polymerase (Takara, Shiga, Japan). Ampliﬁed
products were separated by agarose gel electrophoresis, and were
used for direct DNA sequencing.Acknowledgments
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